GlucoTrack AI Stock Analysis
Want to see GCTK full AI Analyst Report?
GlucoTrack (GCTK) AI Stock Analysis
GlucoTrack
(Other OTC:GCTK)
The score is driven primarily by weak financial performance (no revenue, sustained losses, and worsening cash burn with negative equity), reinforced by a bearish technical trend (well below major moving averages and negative MACD). Corporate events add further risk via Nasdaq delisting/OTC transition and repeated reverse splits alongside dilution-prone financing, while valuation support is limited due to losses and no dividend.
GlucoTrack (GCTK) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $179.58K
- Dividend Yield
- ―
- Average Volume (3M)
- 1.84M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 2.92
- Revenue Growth
- ―
- EPS Growth
- 99.51%
- Country
- US
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
GlucoTrack Business Overview & Revenue Model
Company Description
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucos...
How the Company Makes Money
null
GlucoTrack Financial Statement Overview
Summary
Financials indicate a high-risk, pre-commercial profile: zero reported revenue across periods, persistent and sizable net losses, and steadily deteriorating operating/free cash flow (accelerating cash burn). While total debt is minimal, stockholders’ equity is negative in the latest TTM, raising financing and dilution risk.
Income Statement
6Very NegativeBalance Sheet
34NegativeCash Flow
8Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -43.00K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -16.02M | -19.35M | -21.93M | -7.08M | -4.41M | -3.94M |
| Net Income | -15.95M | -19.39M | -22.60M | -7.10M | -4.43M | -4.07M |
Balance Sheet | ||||||
| Total Assets | 1.50M | 7.84M | 5.93M | 4.91M | 2.44M | 6.26M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M |
| Total Debt | 19.00K | 33.00K | 267.00K | 196.00K | 195.00K | 250.00K |
| Total Liabilities | 3.24M | 5.01M | 18.93M | 1.71M | 1.21M | 1.11M |
| Stockholders Equity | -1.74M | 2.83M | -13.00M | 3.20M | 1.23M | 5.16M |
Cash Flow | ||||||
| Free Cash Flow | -16.31M | -15.34M | -12.59M | -6.56M | -3.73M | -3.77M |
| Operating Cash Flow | -16.22M | -15.24M | -12.49M | -6.56M | -3.73M | -3.77M |
| Investing Cash Flow | -87.00K | -96.00K | -104.00K | 0 | 1,000 | -1,000 |
| Financing Cash Flow | 7.88M | 17.04M | 13.74M | 8.73M | 0 | 0 |
GlucoTrack Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GCTK, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 2.56, and below the 200-day MA of 18.06, indicating a bearish trend. The MACD of -0.74 indicates Negative momentum. The RSI at 28.02 is Positive, neither overbought nor oversold. The STOCH value of 0.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GCTK.
GlucoTrack Risk Analysis
GlucoTrack disclosed 57 risk factors in its most recent earnings report. GlucoTrack reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksGlucoTrack Peers Comparison
Overall Rating
FEMY43Neutral
WOK43Neutral- GCTK39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FEMY | 43Neutral | $11.73M | -0.31 | -225.98% | ― | 21.86% | 73.27% |
| WOK | 43Neutral | $5.58M | -0.01 | -18.55% | ― | ― | ― |
| GCTK | 39Underperform | $284.19K | -0.00 | -2135.52% | ― | ― | 99.51% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GCTK | Glucotrack, Inc. | 0.22 | -155.78 | -99.86% | |
| FEMY | Femasys, Inc. | 1.42 | -14.51 | -91.08% | |
| WOK | WORK Medical Technology Group LTD | 1.20 | -40898.80 | -100.00% |
GlucoTrack Corporate Events
GlucoTrack Faces Nasdaq Delisting, Moves to OTC Market
NegativeOn October 28, 2026, GlucoTrack received notice that a Nasdaq Hearings Panel had decided to delist the company’s securities after its closing bid price fell to $0.87 on October 14, 2026, breaching a conditional exception that required the stock to re...
GlucoTrack Announces Recent Reverse Stock Split Restructuring
NegativeGlucoTrack has implemented a one-for-two reverse stock split of its common shares, effective October 23, 2026, following an earlier one-for-fifteen split on August 28, 2026, reducing its outstanding stock from 2,368,237 to about 1,184,119 shares with...
GlucoTrack completes structured financing and reverse stock split
NegativeOn October 22, 2026, Glucotrack completed a private placement, issuing $2.56 million in senior secured convertible notes for $2 million in cash and five‑year warrants for 8,025,360 shares, alongside placement agent compensation warrants. The financin...
GlucoTrack Announces New Private Placement Warrant Issuance
PositiveOn October 13, 2026, GlucoTrack entered into a Waiver Agreement with certain warrant holders, relaxing prior restrictions on issuing new common stock or equivalents and terminating specified exercise price adjustments on existing warrants for those w...
GlucoTrack Tightens Terms in Recent Financing Amendments
NeutralOn July 14, 2026, Glucotrack entered into a securities purchase agreement with bridge investors for senior secured convertible promissory notes and stock purchase warrants, followed by a joinder on August 4, 2026, and began executing amendments to th...
GlucoTrack Announces Debt-Reducing Public Equity Offering
PositiveOn September 24, 2026, Glucotrack, Inc. priced a “best efforts” public offering comprising 169,388 shares of common stock at $2.04 per share and pre-funded warrants for up to 1,350,220 shares at $2.039 each, for expected gross proceeds of about $3.1...
GlucoTrack and Lōkahi Outline Post-Merger Strategic Focus
PositiveOn September 23, 2026, Lōkahi Therapeutics and Glucotrack CEO Erik Emerson issued a strategic update following their July 14 strategic business combination, clarifying that Glucotrack Technologies remains a wholly owned subsidiary focused on continuo...
GlucoTrack Director Resigns Amid Merger Conflict Concerns
NegativeOn September 14, 2026, Glucotrack, Inc. announced that director Paul V. Goode resigned from its Board of Directors, effective immediately. Goode cited the potential for a conflict of interest between the company and its subsidiary, arising from ongoi...
GlucoTrack Amends Warrant Terms Pending Shareholder Approval
PositiveOn August 4, 2026, GlucoTrack entered a private placement with an investor, issuing pre-funded warrants and common stock purchase warrants. On September 14, 2026, the parties amended the common warrants to prohibit any exercise or share issuance unti...
GlucoTrack Announces Convertible Note Financing to Boost Liquidity
NeutralOn September 10, 2026, Glucotrack entered into definitive agreements with investors for a private placement of senior secured convertible notes with an aggregate principal amount of about $11.6 million. The structure delivers roughly $4.5 million in...
GlucoTrack Settles Disputed Debt with Convertible Note
NegativeOn September 4, 2026, Glucotrack, Inc. entered into a Settlement and Release Agreement with Alto Opportunity Master Fund and other parties to resolve disputes tied to about $10.9 million in indebtedness owed by Apimeds Pharmaceuticals US, Inc. Under...
GlucoTrack Executes Reverse Stock Split to Restructure Shares
NeutralGlucoTrack implemented a one-for-15 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on Aug. 28, 2026, following shareholder approval at its Aug. 18, 2026 annual meeting. The move consolidated every 15 issued and outstandi...
GlucoTrack Announces 1-for-15 Reverse Stock Split
NeutralOn August 27, 2026, Glucotrack, Inc. announced it would implement a 1-for-15 reverse stock split of its common stock, effective at the opening of trading on August 31, 2026, with the shares continuing to trade on Nasdaq under the symbol GCTK. The act...
GlucoTrack Shareholders Approve Key Governance and Capital Actions
PositiveOn August 18, 2026, Glucotrack, Inc. held its annual meeting of stockholders, where shareholders elected six directors to serve until the 2027 meeting and approved, on an advisory basis, the 2025 executive compensation of the company’s named executiv...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026